""*The more we study, the more we discover our ignorance*".Percy Bysshe Shelley"

New genomic technologies and epigenetic research are unraveling the pathophysiological pathways underlying neurological and psychiatric diseases, including Alzheimer\'s disease, Parkinson\'s disease, multiple sclerosis, autism, migraine, schizophrenia, major depression, and other disorders of the nervous system. Interactions between genetic factors, epigenetic profile, environmental risk and other pathological mechanisms are being dissected with increasing depth. The identification of molecular mechanisms, such as aberrant gene silencing, over expression or production of toxic RNAs and/or proteins, reveals the importance of genomic regulation. While this brings hope for improved therapeutics, translational neurogenomics is challenged by the variability in disease penetrance and spectrum of clinical manifestations, severity and evolution. Furthermore, although new molecular discoveries and bioinformatics programs are rapidly improving diagnostic algorithms and laboratory methods, the application of this new genomic knowledge to appropriate clinical care has yet to be fully validated. This special issue of the Journal of Applied & Translational Genomics (ATG) addresses a variety of subjects in this rapidly advancing arena, and with a broad geographical representation.

The paper by Dodgen and collaborators, who did not find association between *CYP2D6* polymorphisms and risperidone adverse effects in the South African population, covers the field of neuro-pharmacogenomics. These authors identified a novel *CYP2D6* polymorphism in this population, emphasizing the need to investigate populations of different ancestries before the clinical use of pharmacogenetic markers can be translated to non-Caucasians. Neuro-pharmacogenomics is also addressed by Benitez and coworkers, who investigated the clinical validity and utility of combinatorial pharmacogenomics to improve psychiatric medication selection. They stress the importance of clinical education about the benefits of pharmacogenomic testing in psychiatry in order to optimize treatment decisions and improve patient outcome. Karikari and Aleksic highlight the potential impact that neurogenomics research can have on Africa\'s science and healthcare. Among the reasons that make the African continent promising to shed new light on the genomics of neuropsychiatric and developmental diseases are its diversity of genetic makeup and gene--environment interactions and the opportunity of traditional medicine for drug discovery. Some challenges, on the other hand, include the scarcity of trained clinical specialists and neuroscientists, sustainable funding and ethical implications of genetic data misuse on vulnerable participants. The commentary "Neurogenomics: An Egyptian Perspective" brings an excellent addition to the current issue of ATG, as it highlights the situation of neurogenomics in Egypt, one of the biggest African countries. The authors underscore various challenges and also propose possible solutions. This is in accordance with the commentary by Karikari and Quansah who discuss the challenges and opportunities for neurogenomics in Ghana. Both commentaries emphasize that improved funding and policy support for neurogenomics research would be important to attract and equip the best-trained scientists in this area. Mohamed and colleagues study the NDUFA12L mitochondrial complex-I assembly factor, showing a nice example of neuroscience research carried out in Africa. These authors conclude that polymorphisms in *NDUFA12L* may play a crucial role in the development of neurodegenerative tauopathies, and suggest that *NDUFA12L* screening might be used to identify risk groups for such disorders. On the other hand, a research paper by Saxena and colleagues presents the Asian work in neuroscience. These authors demonstrate a role for antioxidant enzymes in chronic brain ischemia using a rat model with bilateral occlusion of the common carotid arteries. This link between oxidative stress and progressive neuronal damage in chronic ischemia may open up therapeutic strategies.

These and other advances in neurogenomics are the basis for novel medical applications, thus finding their way into the clinical arena. The report of a young patient with progressive spastic paraplegia diagnosed with SPG11, by Cristina Castro and colleagues, inaugurates a section in the journal dedicated to genomics case reports. The authors emphasize the importance of combining high-throughput sequencing technologies with skilled, thorough clinical evaluation in order to maximize the diagnostic efficacy of next generation sequencing. When it comes to diagnosing genetic neuropsychiatric disorders with genomic analyses, psychological and ethical questions that have to be handled appropriately arise. This is the focus of the paper by Ryan and coworkers, who review the context of genetic counseling in adolescent psychiatry. The authors provide insightful reflections on the main issues and address some elements of the genetic counseling protocol that may help maximize its benefits and minimize potential harm. In a broader sense, handling ethical, legal and social issues is a challenge for any genomic research on neuropsychiatric and neurodevelopmental disorders, since the traits investigated are related with the very essence of human individuality: cognition, personality and behavior. This is the focus of the paper by Canli and collaborators, who refer to neurogenethics as an emerging discipline at the intersection of ethics, neuroscience and genomics.

Finally, we would like to express our deep gratitude to the authors and reviewers of this Special Issue. We hope that you will find these articles instructive and thought provoking. We welcome your opinions and feedback about this issue of ATG, as well as Letters to the Editor. Please send your comments to the editorial office.
